(Melbourne, AT) Mesoblast has been granted Regenerative Medicine Advanced Therapy by the US FDA for its mesenchymal precursor cell (MPC) to treat congestive heart failure.
Mesoblast Receives FDA Regenerative Medicine Advanced Therapy Designation for Its Cell Therapy in Heart Failure Patients With Left Ventricular Assist Devices (Globe Newswire)
